

Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK

Nick Andrews^{1,2}, Elise Tessier¹, Julia Stowe¹, Charlotte Gower¹, Freja Kirsebom¹, Ruth Simmons¹, Eileen Gallagher¹, Meera Chand^{1,3}, Kevin Brown¹, Shamez N Ladhani^{1,4}, Mary Ramsay^{1,2}, Jamie Lopez Bernal^{1,2,5}

Affiliations:

1. Public Health England, London, UK
2. NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, UK
3. Guys and St Thomas's Hospital NHS Trust, London, UK
4. Paediatric Infectious Diseases Research Group, St. George's University of London, UK
5. NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, London, UK

	All		90.3 (87.0 to 92.7)	95.0 (93.8 to 96)	94.8 (88.4 to 97.7)
Comirnaty	80+	All	78.5 (68.1 to 85.5)	81.7 (76.2 to 85.9)	67.1 (31.1 to 84.3)
	65+	All	85.2 (75.3 to 91.1)	94.0 (90.3 to 96.4)	
	40 to 64	All	94.9 (86.4 to 98.1)		92.8 (87.7 to 95.7)


Table S6. Vaccine effectiveness against Alpha hospitalisation among individuals with two doses of Vaxzevria, Comirnaty in England at 1 week, 2 to 9 weeks and 10+ weeks.

Vaccine	Age group	Subgroup	Dose 2		
			week 1	2 to 9 weeks	10+
Vaxzevria	All	All	90.1 (68.8 to 96.8)		93.8 (84.7 to 97.5)
	65+	All	90.7 (27.8 to 98.8)	92.6 (62.6 to 98.5)	
	40 to 64	All	87.0 (3.7 to 98.2)	79.8 (29.2 to 94.3)	
Comirnaty	All	All	96.5 (75.4 to 99.5)	97.8 (91.0 to 99.5)	
	80+	All	88.7 (64.1 to 96.4)	93.6 (84.1 to 97.4)	91.9 (26.9 to 99.1)
	65+	All	90.4 (27.0 to 98.7)		100.0 (0 case, 877 con)
	40 to 64	All	100.0 (0 cases, 1566 con)	79.1 (8.9 to 95.2)	


Supplementary Figures

Supplementary Figure S1. Vaccine effectiveness against Delta hospitalisation (age 40 to 64 years) by clinical risk group status.


a) In a clinical risk group



b) Not in a clinical risk group



Supplementary Figure S2. Vaccine effectiveness of Comirnaty (PF) against symptomatic disease (Delta variant) in people aged 80+ with either a short (≤ 4 weeks) or long (≥ 8 weeks) interval between first and second doses.



Supplementary Figure S3. Vaccine effectiveness against hospitalization age ≥ 65 , all vaccines combined for intervals after the second dose

